NASDAQ:BNTX

BioNTech (BNTX) Stock Forecast, Price & News

$101.86

-1.26 (-1.22%)

(As of 09/26/2023 ET)

Compare

Today's Range: $101.09
▼
$102.64
50-Day Range: $98.50
▼
$125.08
52-Week Range: $95.50
▼
$188.99

Volume: 419,068 shs
Average Volume: 683,853 shs
Market Capitalization: $24.55 billion

P/E Ratio: 5.71
Dividend Yield: N/A
Price Target: $158.69

BioNTech MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 55.8% Upside
$158.69 Price Target
Short Interest: Healthy
1.01% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.86
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -64.05%
From $6.62 to $2.38 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

434th out of 964 stocks

Biological Products, Except Diagnostic Industry

61st out of 157 stocks

3.3

Analyst's Opinion

Consensus Rating
BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $158.69, BioNTech has a forecasted upside of 55.8% from its current price of $101.86.
Amount of Analyst Coverage
BioNTech has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.01% of the outstanding shares of BioNTech have been sold short.
Short Interest Ratio / Days to Cover
BioNTech has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BioNTech has recently increased by 15.64%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioNTech does not currently pay a dividend.
Dividend Growth
BioNTech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BNTX.

3.3

News and Social Media Coverage

News Sentiment
BioNTech has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for BioNTech this week, compared to 6 articles on an average week.
Search Interest
33 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.
MarketBeat Follows
13 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioNTech insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.52% of the stock of BioNTech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BioNTech are expected to decrease by -64.05% in the coming year, from $6.62 to $2.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioNTech is 5.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.06.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioNTech is 5.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.33.
Price to Book Value per Share Ratio
BioNTech has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioNTech (NASDAQ:BNTX) Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Price History

30 days | 90 days | 365 days | Advanced Chart

BNTX Stock News Headlines

September 7, 2023 | marketbeat.com

3 Stocks to Buy For the COVID Resurgence (BNTX)

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

September 23, 2023 | finance.yahoo.com

BioNTech SE's (NASDAQ:BNTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

September 27, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

September 23, 2023 | msn.com

BioNTech Is Revising Plans for African Vaccine Factory Network

September 19, 2023 | ca.news.yahoo.com

BioNTech wins up to $90 million in funding for mpox vaccine development

September 18, 2023 | news.yahoo.com

BioNTech partners with CEPI to advance development of mpox vaccine

September 18, 2023 | benzinga.com

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI's 100 Days Mission

September 18, 2023 | markets.businessinsider.com

BioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166

September 27, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

September 15, 2023 | markets.businessinsider.com

More Than Half Of Americans Want New COVID-19 Booster, But Ron DeSantis Will Fight Virus With His Charisma Alone

September 13, 2023 | msn.com

BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost

September 12, 2023 | msn.com

CDC recommends COVID-19 shots for people age six months and older (update)

September 11, 2023 | marketwatch.com

Pfizer, BioNTech Get FDA OK for Updated Covid-19 Vaccine >PFE BNTX

September 7, 2023 | msn.com

MHRA grants approval for Pfizer-BioNTech’s adapted vaccine for Covid-19

September 6, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA), Dexcom (DXCM) and BioNTech SE (BNTX)

September 5, 2023 | finance.yahoo.com

Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle

September 1, 2023 | msn.com

Europe Approves Pfizer/BioNTech's Adapted COVID-19 Vaccine For Upcoming Autumn Vaccination Campaigns

September 1, 2023 | theglobeandmail.com

EU authorizes use of adapted Pfizer/BioNtech vaccine for COVID-19 variant

August 30, 2023 | finanznachrichten.de

BioNTech SE: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

August 30, 2023 | benzinga.com

BioNTech Unusual Options Activity For August 30

August 30, 2023 | markets.businessinsider.com

Pfizer, BioNTech Obtain Positive CHMP Opinion For Omicron XBB.1.5-adapted COVID-19 Vaccine In EU

August 30, 2023 | finance.yahoo.com

Insiders own 20% of BioNTech SE (NASDAQ:BNTX) shares but private equity firms control 44% of the company

August 30, 2023 | finance.yahoo.com

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

August 28, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on BioNTech SE (BNTX)

August 28, 2023 | benzinga.com

Why BioNTech Shares Are Rising During Monday's Session

August 22, 2023 | baystreet.ca

How to Play the Covid Vaccine Rally

August 22, 2023 | msn.com

Vaccine makers light up as COVID hospitalizations rise

See More Headlines

Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Company Calendar

Last Earnings: 8/07/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BNTX
CUSIP: N/A
CIK: 1776985
Web: www.biontech.de
Phone: 49-61-31908-40
Fax: 49-6131-908-4390
Employees: 4,530
Year Founded: 2008

Price Target and Rating

Average Stock Price Forecast: $158.69
High Stock Price Forecast: $260.00
Low Stock Price Forecast: $116.00
Forecasted Upside/Downside: +55.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $17.84
Trailing P/E Ratio: 5.71
Forward P/E Ratio: 15.39
P/E Growth: N/A
Net Income: $9.94 billion
Net Margins: 47.37%
Pretax Margin: 62.27%
Return on Equity: 21.46%
Return on Assets: 18.71%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 10.56
Quick Ratio: 10.32

Sales & Book Value

Annual Sales: $18.24 billion
Price / Sales: 1.35
Cash Flow: $40.42 per share
Price / Cash Flow: 2.52
Book Value: $87.07 per share
Price / Book: 1.17

Miscellaneous

Outstanding Shares: 240,990,000
Free Float: 194,720,000
Market Cap: $24.55 billion
Optionable: Not Optionable
Beta: 0.17

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Prof. Ugur Sahin M.D. (Age 58)
Co-Founder, CEO & Chair of the Management Board
Comp: $479.34k

Dr. Ozlem Tureci M.D. (Age 56)
Co-Founder, Chief Medical Officer & Member of Management Board
Comp: $890.97k

Mr. Jens H. Holstein (Age 60)
CFO & Member of Management Board
Comp: $938.26k

Dr. Sierk Poetting Ph.D. (Age 50)
MD, COO & Member of Management Board
Comp: $985.54k

Mr. Ryan Richardson (Age 44)
Chief Strategy Officer, MD & Member of Management Board
Comp: $476.11k

Mr. Sean Marett (Age 58)
Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
Comp: $913.54k

Dr. James Timothy Patrick Ryan Ph.D. (Age 48)
Chief Legal Officer & Member of the Management Board

Sylke Maas Ph.D.
VP of Investor Relations and Bus. Strategy

Michael Boehler
MD & Head of Global External Communications

Dr. Oliver Hennig Ph.D.
Sr. VP of Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BNTX Stock - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 5 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.
View BNTX analyst ratings or view top-rated stocks.
What is BioNTech's stock price forecast for 2023?: 10 equities research analysts have issued 12-month price targets for BioNTech's stock. Their BNTX share price forecasts range from $116.00 to $260.00. On average, they expect the company's share price to reach $158.69 in the next year. This suggests a possible upside of 55.8% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.
How have BNTX shares performed in 2023?: BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 32.2% and is now trading at $101.86.
View the best growth stocks for 2023 here.
When is BioNTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BNTX earnings forecast.
How were BioNTech's earnings last quarter?: BioNTech SE (NASDAQ:BNTX) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.04. The business earned $167.70 million during the quarter, compared to analyst estimates of $628.13 million. BioNTech had a net margin of 47.37% and a trailing twelve-month return on equity of 21.46%. BioNTech's quarterly revenue was down 94.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $7.31 earnings per share.
What ETFs hold BioNTech's stock?: ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB).
What is Ugur Sahin's approval rating as BioNTech's CEO?: 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.
What other stocks do shareholders of BioNTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?: (BNTX) raised $251 million in an initial public offering on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.
What is BioNTech's stock symbol?: BioNTech trades on the NASDAQ under the ticker symbol "BNTX."
Who are BioNTech's major shareholders?: BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.09%), Temasek Holdings Private Ltd (1.88%), Flossbach Von Storch AG (1.43%), Artisan Partners Limited Partnership (0.84%), BlackRock Inc. (0.72%) and Capital World Investors (0.38%).
How do I buy shares of BioNTech?: Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioNTech's stock price today?: One share of BNTX stock can currently be purchased for approximately $101.86.
How much money does BioNTech make?: BioNTech (NASDAQ:BNTX) has a market capitalization of $24.55 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $17.84 on an earnings per share basis.
How many employees does BioNTech have?: The company employs 4,530 workers across the globe.
Does BioNTech have any subsidiaries?: The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
How can I contact BioNTech?: BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.

This page (NASDAQ:BNTX) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial